B+
Bull case
30%
Probability
Target price
$57.00
+55.6% vs current
TGTX
TG TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$44.50
+21.5% vs current
B-
Bear case
20%
Probability
Target price
$28.50
-22.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+72.2
Score
AI commentary
The tone is constructive and mostly company-release driven: the May 6 update showed BRIUMVI revenue and guidance still accelerating, and the May 27 ENHANCE data added another meaningful de-risking step. Trusted coverage pointed to a positive post-release stock reaction, but analyst revision depth in the packet is thin and there is no social context to lean on, so conviction stays moderate rather than aggressively bullish.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ1 2026 commercial update and guidance raise stayed strongMedium impact
The company reported first-quarter 2026 total revenue of about $204.9M, including $194.8M of BRIUMVI U.S. net product revenue, and raised full-year 2026 BRIUMVI U.S. net product revenue guidance to $885M-$900M. That keeps the core commercial thesis intact and supports the view that BRIUMVI is still early in its adoption curve.
2026-05-27eventPhase 3 ENHANCE met its primary endpointHigh impact
On May 27, TG Therapeutics said the ENHANCE Phase 3 trial met its primary endpoint, showing bioequivalent exposure for a single 600 mg Day 1 infusion versus the approved Day 1/Day 15 initiation regimen, with safety and tolerability consistent with the existing profile. The company said it is targeting a supplemental BLA in 2H-2026. [#8-K-2026-05-27]
2026-12-31catalystSingle-infusion BRIUMVI could lift convenience and adoption if approvedMedium impact
If the consolidated initiation regimen is approved, BRIUMVI could become a simpler starting option for RMS and may improve infusion-center throughput and time-to-treatment, which would be a longer-duration adoption tailwind. The upside still depends on FDA review, payer access, and whether convenience translates into broader prescribing. [#8-K-2026-05-27]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology